These proposed studies directly address 3 RFA objectives. First, we offer a basic/translational sciencestudy that considers local urogenital tract factors in the pathogenesis of UCPPS. Second, we address RFArequest for studies to identify and validate biomarkers for UCPPS. Our strategy uses cutting-edge proteomicanalysis of urine specimens from patients with IC/PBS and CP/CPPS in a new approach to identify andvalidate new biomarkers that potentially could improve diagnosis, predict UCPPS natural history, and predict ormeasure response to treatment. Third, this work also addresses the RFA priority to elucidate the pathogenesisof UCPPS. These protein/peptide markers may act via specific cellular pathways important to UCPPSpathology. Notably, if successful, this technology can be exported across the Network and could establish afoundation for future clinical trials and for more targeted therapies to treat specific urothelial defects.
Showing the most recent 10 out of 49 publications